Should we centralise care for the patient suspected of having ovarian malignancy?

Gynecologic Oncology

Volumn 122, Issue 1, 2011, Pages 95-99

  Geomini, Peggy M A J ^a   Kruitwagen, Roy F P M ^b,c   Bremer, Gérard L ^d   Massuger, Leon ^e   Mol, Ben Willem J ^a,f  

^a MÁXIMA MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d Zuyderland Medical Centre   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Centralised care; Cost effective analysis; Gynecologic oncologist; Ovarian cancer; Risk of malignancy index

Indexed keywords

CISPLATIN; PACLITAXEL;

ADNEXA DISEASE; ARTICLE; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; FEMALE; HIGH RISK POPULATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NETHERLANDS; OVARY CANCER; PATIENT CARE; PRIORITY JOURNAL;

COST-BENEFIT ANALYSIS; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; GYNECOLOGY; HUMANS; MEDICAL ONCOLOGY; NEOPLASM STAGING; NETHERLANDS; OVARIAN NEOPLASMS; RISK ASSESSMENT; SPECIALIZATION;

EID: 79957762546     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.03.005     Document Type: Article

References (17)

1. Vernooij F, Heintz P, Witteveen E, van der GY. The outcomes ovarian cancer treatment are better when provided by gynecologic oncologists specialized hospitals systematic review. Gynecol Oncol 2007;105:801-12.
2. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organization for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003 January 15;95:113-25. (Pubitemid 36193260)
3. Vernooij F, Heintz AP, Witteveen PO, van der Heiden-van der Loo, Coebergh JW, vander GY. Specialized care and survival ovarian cancer patients The Netherland: nationwide cohort study. J Natl Cancer Inst 2008 March 19;100:399-406. (Pubitemid 351480512)
4. Geomini PM, Kluivers KB, Moret E, Bremer GL, Kruitwagen RF, Mol BW. Evaluation of adnexal masses with threedimensional ultrasonography. Obstet Gynecol 2006;108:1167-75. (Pubitemid 44665412)
5. Carney ME, Lancaster JM, Ford C, Tsodikov A, Wiggins CL. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 2002;84:36-42.
6. Engelen MJ, Kos HE, Willemse PH, Aalders JG, de Vries EG, Schaapveld M, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006;106:589-98. (Pubitemid 43157622)
7. Junor EJ, Hole DJ, McNulty L, Mason M, Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 1999;106:1130-6.
8. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate pre-operative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-9. (Pubitemid 20340625)
9. Geomini PMAJ, Kruitwagen RFPM, Bremer GL, Cnossen J, Mol BW. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 2009;113:384-439.
10. DBC onderhoud. Available at http://www.dbconderhoud.nlRef type: Electronic citation.
11. Pharmacotherautic Compass 2009. Available at http://www.fk.cvz.nl.2009. Health care insurance boardRef type: Electronic citation.
12. Schueler JA. Early ovarian carcinoma surgical staging and prognostic factors. Eur J Obstet Gynecol Reprod Biol 1999;85:127-9. (Pubitemid 29313374)
13. Bristow RE, Santillan A, az-Montes TP, Gardner GJ, Giuntoli RL, Meisner BC. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer 2007;109:1513-22.
14. Greving JP, Vernooij F, Heintz AP, Graaf Y, Buskens E. Is centralization of ovarian cancer warranted? A cost-effectiveness analysis. Vernooij F, editor. Thesis: Ovarian cancer treatment in The Netherlands 1996-2003, 100-116. 2008.
15. Sassone AM, Timor-Tritsch IE, Artner A, Westhoff C, Warren WB. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991;78:70-6.
16. Tingulstad S, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsen T, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the preoperative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996;103:826-31. (Pubitemid 26291762)
17. Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999;93:448-52. (Pubitemid 29107011)